Ribomic Inc. (4591.T)
JPY 80.0
(0.0%)
JPY 80.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.09 Billion JPY | 25.68% |
| 2022 | -2.82 Billion JPY | 2.64% |
| 2021 | -2.9 Billion JPY | 13.07% |
| 2020 | -3.33 Billion JPY | -108.5% |
| 2019 | -1.6 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.74 Billion JPY | 16.7% |
| 2023 Q4 | -2.09 Billion JPY | -1.72% |
| 2023 Q3 | -2.06 Billion JPY | -5.46% |
| 2023 Q2 | -1.95 Billion JPY | 16.12% |
| 2023 Q1 | -2.33 Billion JPY | 17.4% |
| 2023 FY | -2.09 Billion JPY | 25.68% |
| 2022 Q3 | -2.64 Billion JPY | -3.91% |
| 2022 Q2 | -2.54 Billion JPY | 0.0% |
| 2022 Q4 | -2.82 Billion JPY | -6.65% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 382.695% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -85.172% |
| GNI Group Ltd. | -17.93 Billion JPY | 88.292% |
| Linical Co., Ltd. | -4.46 Billion JPY | 52.955% |
| Trans Genic Inc. | -221.16 Million JPY | -849.384% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 52.214% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 56.164% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 246.473% |
| AnGes, Inc. | -3.79 Billion JPY | 44.711% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -398.98% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 108.43% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -321.505% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -350.253% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 22.408% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -11.203% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -113.792% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 38.189% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -102.961% |
| Kidswell Bio Corporation | 343.58 Million JPY | 711.121% |
| PeptiDream Inc. | 3.29 Billion JPY | 163.783% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -115.891% |
| SanBio Company Limited | -3.78 Billion JPY | 44.594% |
| Healios K.K. | -2.19 Billion JPY | 4.121% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -122.228% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 19.984% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -48.176% |
| StemRIM | -8.41 Billion JPY | 75.033% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 55.167% |
| FunPep Company Limited | -1.79 Billion JPY | -17.083% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 1.72% |
| Stella Pharma Corporation | -1.11 Billion JPY | -87.577% |
| TMS Co., Ltd. | -3.44 Billion JPY | 39.078% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 62.206% |
| Cuorips Inc. | -5.56 Billion JPY | 62.242% |
| K Pharma,Inc. | -3.26 Billion JPY | 35.717% |
| Takara Bio Inc. | -32.2 Billion JPY | 93.48% |
| ReproCELL Incorporated | -2.93 Billion JPY | 28.557% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -217.681% |
| StemCell Institute Inc. | -2.83 Billion JPY | 25.981% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -1.616% |
| CellSeed Inc. | -2.01 Billion JPY | -4.359% |